Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials

Gissy, Jacob J.; Johnson, Teresa; Fox, Deborah J.; Kumar, Anil; Ciafaloni, Emma; van Essen, Anthonie J.; Peay, Holly L.; Martin, Ann; Lucas, Ann; Finkel, Richard S.

doi:10.1016/j.nmd.2017.06.002

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials

Published Date:

Jul 21 2017

Publisher's site:

http://dx.doi.org/10.1016/j.nmd.2017.06.002 New Site Icon

Source:

Neuromuscul Disord. 27(10):905-910.

Language:

English

[PDF-484.63 KB]

Details:

Alternative Title:

Neuromuscul Disord

Personal Author:

Gissy, Jacob J. ; Johnson, Teresa ; Fox, Deborah J. ; Kumar, Anil ; Ciafaloni, Emma ; ... More ▼

Corporate Authors:

MD STARnet

Description:

Individuals with Duchenne muscular dystrophy (DMD) often exhibit delayed motor and cognitive development, including delayed onset of ambulation. Data on age when loss of independent ambulation occurs are well established for DMD; however, age at onset of walking has not been well described. We hypothesize that an effective medication given in early infancy would advance the age when walking is achieved so that it is closer to age-matched norms, and that this discrete event could serve as the primary outcome measure in a clinical trial. This study examined three data sets, Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet); Dutch Natural History Survey (DNHS); and Parent Project Muscular Dystrophy (PPMD). The distribution of onset of ambulation in DMD (mean ± SD) and median age, in months, at the onset of ambulation was 17.3 (±5.5) and 16.0 in MD STARnet, 21.8 (±7.1) and 20.0 in DNHS, and 16.1 (±4.4) and 15 in PPMD. Age of ambulation in these data sets were all significantly later (P <0.001) than the corresponding age for typically developing boys, 12.1 (±1.8). A hypothetical clinical trial study design and power analyses are presented based on these data.

Subject:

[+]

Pubmed ID:

28739181

Pubmed Central ID:

PMC5628390

Document Type:

Journal Article

Funding:

U01 DD000392/DD/NCBDD CDC HHS/United States ; U01 DD000187/DD/NCBDD CDC HHS/United States ; U01 DD001123/DD/NCBDD CDC HHS/United States ; U01 DD000189/DD/NCBDD CDC HHS/United States ; CC999999/Intramural CDC HHS/United States ; ... More ▼

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

Supporting Files:

	nihms904522.nxml	text/xml
	nihms904522f1.gif	image/gif
	nihms904522f1.jpg	image/jpeg
	nihms904522f2.gif	image/gif
	nihms904522f2.jpg	image/jpeg

No Related Documents.

You May Also Like:

Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet

Personal Author:

Ciafaloni, Emma; Kumar, Anil; Liu, Ke; Pandya, Shree; Westfield, Christina; Fox, Deborah J.; Caspers Conway, Kristin M.; Cunniff, Christopher; Mathews, Katherine; West, Nancy; Romitti, Paul A.; McDermott, Michael P.;

Published Date:

2016

Source:

J Pediatr Rehabil Med. 9(1):5-11.

Description:

PURPOSEWe investigated the prognostic utility of onset age at first signs and symptoms (SS) to predict onset age at loss of ambulation (LOA) for childhood-onset Duchenne and Becker Muscular Dystrophies (DBMD).METHODSOur cohort comprised male cases wi...

File Type:

[PDF - 263.69 KB]
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management

Personal Author:

Birnkrant, David J; Bushby, Katharine; Bann, Carla M; Apkon, Susan D; Blackwell, Angela; Brumbaugh, David; Case, Laura E; Clemens, Paula R; Hadjiyannakis, Stasia; Pandya, Shree; Street, Natalie; Tomezsko, Jean; Wagner, Kathryn R; Ward, Leanne M; Weber, David R;

Corporate Authors:

for the DMD Care Considerations Working Group

Published Date:

Feb 03 2018

Source:

Lancet Neurol. 17(3):251-267.

Description:

Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in 2010, multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In conjunction with improved patient survival, a shift to more anticipat...

File Type:

[PDF - 778.05 KB]
Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet

Personal Author:

Weber, David R.; Thomas, Shiny; Erickson, Stephen W.; Fox, Deborah; Oleszek, Joyce; Pandya, Shree; Venkatesh, Yedatore; Westfield, Christina; Ciafaloni, Emma;

Corporate Authors:

Muscular Dystrophy Tracking and Research Network (MD STARnet)

Published Date:

2018

Source:

J Neuromuscul Dis. 5(4):497-507

Description:

Background:Patients with Duchenne muscular dystrophy (DMD) are at high risk of endocrine and bone health complications resulting from the high glucocorticoid (GC) doses used to treat this condition. There are limited data characterizing the clinical ...

File Type:

[PDF - 1.20 MB]
SIBLING CONCORDANCE FOR CLINICAL FEATURES OF DUCHENNE AND BECKER MUSCULAR DYSTROPHIES

Personal Author:

PETTYGROVE, SYDNEY; LU, ZHENQIANG; ANDREWS, JENNIFER G.; MEANEY, F. JOHN; SHEEHAN, DANIEL W.; PRICE, ELINORA T.; FOX, DEBORAH J.; PANDYA, SHREE; OUYANG, LIJING; APKON, SUSAN D.; POWIS, ZOE; CUNNIFF, CHRISTOPHER;

Published Date:

Jun 2014

Source:

Muscle Nerve. 2013; 49(6):814-821.

Description:

IntroductionThe correlation of markers of disease severity among brothers with Duchenne or Becker muscular dystrophy has implications for clinical guidance and clinical trials.MethodsSibling pairs with Duchenne or Becker muscular dystrophy (n = 60) w...

File Type:

[PDF - 395.73 KB]
Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

Personal Author:

Kim, Sunkyung; Campbell, Kimberly A.; Fox, Deborah J.; Matthews, Dennis J.; Valdez, Rodolfo;

Corporate Authors:

MD STAR

Published Date:

Nov 20 2014

Source:

J Child Neurol. 30(10):1275-1280.

Description:

This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified b...

File Type:

[PDF - 498.45 KB]